TrialChinese journal of integrative medicine2018

Gefitinib plus Fuzheng Kang'ai Formula () in Patients with Advanced Non-Small Cell Lung Cancer with Epidermal Growth Factor Receptor Mutation: A Randomized Controlled Trial.

Xiao-Bing Yang et al.PubMed ↗Publisher ↗

No numbers read from the abstract.